Elite Pharmaceuticals, Inc.
ELTP
$0.40
-$0.021-4.99%
OTC PK
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 70.00M | 71.17M | 66.45M | 56.63M | 47.32M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 70.00M | 71.17M | 66.45M | 56.63M | 47.32M |
| Cost of Revenue | 39.09M | 39.34M | 36.37M | 30.27M | 25.64M |
| Gross Profit | 30.91M | 31.83M | 30.08M | 26.36M | 21.68M |
| SG&A Expenses | 9.43M | 8.40M | 7.65M | 7.31M | 5.79M |
| Depreciation & Amortization | 1.66M | 1.57M | 1.48M | 1.38M | 1.33M |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 57.82M | 56.56M | 53.40M | 45.84M | 40.35M |
| Operating Income | 12.18M | 14.61M | 13.05M | 10.79M | 6.97M |
| Income Before Tax | -17.33M | -6.77M | 14.10K | 463.10K | -2.39M |
| Income Tax Expenses | 655.90K | -383.90K | -19.57M | -19.65M | -17.94M |
| Earnings from Continuing Operations | -17.99 | -6.39 | 19.58 | 20.11 | 15.55 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -17.99M | -6.39M | 19.58M | 20.11M | 15.55M |
| EBIT | 12.18M | 14.61M | 13.05M | 10.79M | 6.97M |
| EBITDA | 13.78M | 16.13M | 14.48M | 12.12M | 8.31M |
| EPS Basic | -0.02 | -0.01 | 0.02 | 0.02 | 0.02 |
| Normalized Basic EPS | -0.01 | -0.01 | 0.00 | 0.00 | 0.00 |
| EPS Diluted | -0.02 | -0.01 | 0.01 | 0.01 | 0.01 |
| Normalized Diluted EPS | -0.01 | -0.01 | 0.00 | 0.00 | 0.00 |
| Average Basic Shares Outstanding | 4.22B | 4.17B | 4.12B | 4.06B | 4.06B |
| Average Diluted Shares Outstanding | 4.25B | 4.20B | 4.15B | 4.09B | 4.07B |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |